Few weeks before the outbreak of COVID-19 pandemic, a multicenter Spanish study demonstrated that early administration of high-dose dexamethasone in patients with established moderate-to-severe ARDS reduced the duration of mechanical ventilation and overall mortality. The aim of our work was to retrospectively review the efficacy of high-dose dexamethasone in patients with SARS-CoV-2 pneumonia-related ARDS admitted to a COVID-19 hub in Lombardy (Italy) during the first wave of the disease.įrom March 4th to April 1st, 2020, all adult patients (≥ 18 years) with confirmed COVID-19 pneumonia (laboratory real-time-polymerase chain reaction SARS-CoV-2 positivity and/or chest computed tomography scan suggestive for interstitial pneumonia) admitted to the High-Intensity Care of the Internal Medicine Department (Ospedale di Circolo – Fondazione Macchi, ASST dei Sette Laghi, Varese, Italy) were included in the present retrospective study.
0 kommentar(er)
